top of page
Selection of publications using our mouse model
Tiedt, R., H. Hao-Shen, M. A. Sobas, R. Looser, S. Dirnhofer, J. Schwaller and R. C. Skoda (2008). "Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice." Blood 111(8): 3931-3940.
Kubovcakova, L., P. Lundberg, J. Grisouard, H. Hao-Shen, V. Romanet, R. Andraos, M. Murakami, S. Dirnhofer, K. U. Wagner, T. Radimerski and R. C. Skoda (2013). "Differential effects of hydroxyurea and INC424 on mutant allele burden and myeloproliferative phenotype in a JAK2-V617F polycythemia vera mouse model." Blood 121(7): 1188-1199.
Characterization of the model
Latest research articles based on our MPN mouse
Usart, M., J. Stetka, D. Luque Paz, N. Hansen, Q. Kimmerlin, T. Almeida Fonseca, M. Lock, L. Kubovcakova, R. Karjalainen, H. Hao-Shen, A. Borsch, A. El Taher, J. Schulz, J. C. Leroux, S. Dirnhofer and R. C. Skoda (2024). "Loss of Dnmt3a increases self-renewal and resistance to pegIFN-alpha in JAK2-V617F-positive myeloproliferative neoplasms." Blood 143(24): 2490-2503.
Usart, M., N. Hansen, J. Stetka, T. Almeida Fonseca, A. Guy, Q. Kimmerlin, S. Rai, H. Hao-Shen, J. Roux, S. Dirnhofer and R. C. Skoda (2024). "The glutaminase inhibitor CB-839 targets metabolic dependencies of JAK2-mutant hematopoiesis in MPN." Blood Adv 8(9): 2312-2325.
Stetka, J., M. Usart, L. Kubovcakova, S. Rai, T. N. Rao, J. Sutter, H. Hao-Shen, S. Dirnhofer, F. Geier, M. S. Bader, J. R. Passweg, V. Manolova, F. Durrenberger, N. Ahmed, T. Schroeder, T. Ganz, E. Nemeth, L. Silvestri, A. Nai, C. Camaschella and R. C. Skoda (2023). "Iron is a modifier of the phenotypes of JAK2-mutant myeloproliferative neoplasms." Blood 141(17): 2127-2140.
Rai, S., E. Grockowiak, N. Hansen, D. Luque Paz, C. B. Stoll, H. Hao-Shen, G. Mild-Schneider, S. Dirnhofer, C. J. Farady, S. Mendez-Ferrer and R. C. Skoda (2022). "Inhibition of interleukin-1beta reduces myelofibrosis and osteosclerosis in mice with JAK2-V617F driven myeloproliferative neoplasm." Nat Commun 13(1): 5346.
Rai, S., Y. Zhang, E. Grockowiak, Q. Kimmerlin, N. Hansen, C. B. Stoll, M. Usart, D. Luque Paz, H. Hao-Shen, Y. Zhu, J. Roux, M. S. Bader, S. Dirnhofer, C. J. Farady, T. Schroeder, S. Mendez-Ferrer and R. C. Skoda (2024). "IL-1beta promotes MPN disease initiation by favoring early clonal expansion of JAK2-mutant hematopoietic stem cells." Blood Adv 8(5): 1234-1249.
Human JAK2-V617F transgene
Cre-mediated expression of the human JAK2-V617F variant
Different MPN phenotypes
By using different Cre models, we can modulate the obtained phenotype: PV, ET or Myelofibrosis.
Well-established model
Since its development in 2008, our mouse strain has been used by many research groups worldwide.
bottom of page